This antibody clone (13G11 1A3 1E3 (aka 13G11 1A3 1A7)) binds ECSCR and inhibits chemotaxis. The antibody may provid a pharmaceutical composition to inhibit tumour cell invasion and for the treatment studies of diseases, for example diseases associated with angiogenesis such as cancer.
Figure 2 is a barchart summarising the results of a Matrigel tube formation assay in which HUVEC branching was compared in the presence of the ECSCR 13GlI antibody, an isotype control, an untreated control and cells treated with ECSCR siRNA. Error bars represent standard deviation and * = p<0.05.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-3014z | Recombinant Anti-Human ECSCR Antibody | ELISA, IP, FuncS | IgG |
There are currently no Customer reviews or questions for TAB-268MZ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.